Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure

@inproceedings{Bartolucci2017SafetyAE,
  title={Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure},
  author={Jorge Bartolucci and Fernando J. Verdugo and Paz L. Gonz{\'a}lez and Ricardo E. Larrea and Ema Abarz{\'u}a and Carlos Goset and Pamela Rojo and Ivan Palma and Rub{\'e}n Lamich and Pablo A. Pedreros and Gloria Valdivia and Valentina M{\"u}ller Lopez and Carolina Nazzal and Francisca Alcayaga-Miranda and Jimena Cuenca and Matthew J. Brobeck and Amit N. Patel and Fernando E Figueroa and Maroun Khoury},
  booktitle={Circulation research},
  year={2017}
}
RATIONALE Umbilical cord-derived mesenchymal stem cells (UC-MSC) are easily accessible and expanded in vitro, possess distinct properties, and improve myocardial remodeling and function in experimental models of cardiovascular disease. Although bone marrow-derived mesenchymal stem cells have been previously assessed for their therapeutic potential in individuals with heart failure and reduced ejection fraction, no clinical trial has evaluated intravenous infusion of UC-MSCs in these patients… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 48 REFERENCES

Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy : POSEIDON - DCM Trial

JM Hare, DL DiFede, AC Rieger
  • J Am Coll Cardiol
  • 2017